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The damage inflicted on the United States population by men-
tal health and substance use issues is reaching epidemic pro-
portions with few signs of abating. When compared to other 
countries, the U.S. possesses the highest death rate from men-
tal health and substance abuse disorders (12 deaths per 1 00 000 
individuals, almost twice as much as the second leading coun-
try).1 Mental health issues are the leading cause of disease bur-
den in the United States for females and the third leading 
cause for males, and the disease burden from drug use disorders 
is four times higher in the U.S. than in comparable countries.1 
The U.S. suicide rate has grown by 18% since 2006,2 with drug 
use linked to higher likelihood of suicidal thoughts and 
behavior.3
Substance use during adolescence lies at the very confluence 
of worsening trends in mental health care.4 Adolescence is 
associated with multiple processes that compound a client’s 
vulnerability that include, but are not limited to: identity for-
mation, greater responsibilities, the influence of peer relations 
in decision making, and the emergence of more complex think-
ing. Developmental factors underpinning impulsivity also con-
tribute to the negative synergistic relationship between 
substance use disorder (SUD) and mental health problems.5
Mental, emotional, and behavioral disorders among youth 
cost the nation $247 billion yearly due to crime, health services, 
and lost productivity.6 Although youth are not necessarily 
involved in the labor market, their disorders can impact fami-
lies and other related systems in ways that have rippling eco-
nomic costs—and costs that do not “readily translate to dollars 
and cents.”6 Many of these costly disorders begin to present 
early in life, suggesting efforts to interdict should be stressed at 
adolescence.7
Resolution of SUD and mental health comorbidity requires 
sophisticated and integrated approaches. Current interventions 
targeting comorbid diagnoses are often undermined by the frus-
trating and substantial likelihood of relapse.4 The difficulty of 
achieving positive clinical outcomes (ie, mental health gains 
along with sobriety) makes evaluation of interventions more dif-
ficult. There are, however, best practices emerging from a grow-
ing body of literature. Such practices usually include 
comprehensive, multimodal interventions that are integrated 
into a single treatment program. These programs begin with 
assessment and followed by attendance, treatment completion, 
and medication compliance throughout an intensive period of 
care coordinated by a single practitioner.4,7
Another reason for treatment difficulties when trying to 
address these complex conditions with adolescents is their inef-
fectiveness when conducted through didactic mediums (e.g., 
listening while sitting in a chair). Adolescents experiencing serious 
psychological distress are seeing or speaking less often with a men-
tal health professional.8 And even when help is sought, 13% of 
mental health discharges and 10% of substance use discharges are 
readmitted to U.S. hospitals within 30 days.8 The need to solidify 
effective treatment programs, as well as investigate new interven-
tion strategies, merits the reexamination of current behavioral 
healthcare treatment. This is especially true in the areas of evi-
dence-based programing, effective treatments, and best practices.
One new and innovative strategy for addressing these needs 
has been the development of outdoor behavioral healthcare 
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(OBH). OBH is an important and rapidly growing clinical 
approach to behavioral healthcare for adolescents. OBH thera-
pists not only deliver the same therapeutic elements often 
implemented in traditional “office therapies,” but supplement 
these approaches with the benefits typically found in other 
healthy ecosystems that create an exponentially richer thera-
peutic environments. OBH consists of:
– Extended backcountry travel and wilderness living 
experiences long enough to allow for clinical assessment, 
establishment of treatment goals, and a reasonable course of 
treatment not to exceed the productive impact of the experi-
ence,
– Active and direct use of clients’ participation and respon-
sibility in their therapeutic process,
– Continual group living and regular formal group ther-
apy sessions to foster teamwork and social interactions,
– Individual therapy sessions, often supported by the 
inclusion of family therapy,
– Adventure experiences utilized to appropriately enhance 
treatment by fostering the development of eustress (ie, the 
positive use of stress) as a beneficial element in the thera-
peutic experience,
– The use of nature in reality as well as a metaphor within 
the therapeutic process, and
– A strong ethic of care and support throughout the ther-
apeutic experience.9
OBH outcome-based research has produced promising 
results over the past 5 years. In one study, 36 Australian adoles-
cent outpatients with substance abuse and comorbid mental 
health issues completed a 70-day manualized wilderness 
adventure therapy program. Statistically significant gains 
(P = .026) in psychological resilience and social self-esteem 
were found at discharge and 3 months post-discharge. For par-
ticipants in clinical ranges prior to the program, there were 
large and positive effect size changes in depressive symptomol-
ogy (g = −0.80; 37% change) as well as with behavioral and 
emotional functioning (g = −0.70; 33% change). All of these 
changes were retained at 3 months following discharge.10
Bettman et  al11 conducted a meta-analysis on the clinical 
effectiveness of wilderness therapy for private pay clients in 
North America. Search processes resulted in a meta-analysis 
based on 36 studies, totaling 2399 participants receiving OBH. 
The meta-analyses found medium effect sizes for all six con-
structs assessed: self-esteem (g = 0.49), locus of control 
(g = 0.55), behavioral observations (g = 0.75), personal effective-
ness (g = 0.46), clinical measures (g = 0.50) and interpersonal 
measures (g = 0.54).11 These findings include greater resilience 
in the face of substance use.
DeMille et al12 examined the longitudinal impact of OBH 
on comorbid adolescents. Findings showed that comorbid ado-
lescents who attended an Outdoor Behavioral Healthcare 
treatment program were functioning significantly better than 
the comparison group 1 year following the program as meas-
ured by the YOQ 2.01.13 Comorbid adolescents who remained 
in their communities were still at acute levels of psychosocial 
dysfunction during the same time span. A regression analysis 
revealed age, race, and gender not to be significant predictors of 
improvement.
Lewis14 reinforced these findings, demonstrating significant 
gains in relieving symptoms related to SUDs and enhancing 
clients’ quality of life. And most importantly, clients main-
tained these significant beneficial changes >1 year 
post-discharge.
The purpose of this study was to evaluate the effectiveness 
of three post-acute behavioral health strategies for treating 
adolescents with substance use and mental illness comorbid 
issues. This study compared the differences between these 
treatment programs on their cost, completion rates, healthcare, 
and societal outcomes. It specifically focused its research on the 
cost-effectiveness analysis on OBH, TAU, and no structured 
treatment (NST) application to comorbid behavioral health-
care issues. The research protocol received full review, protec-
tion, and approval of the Institutional Review Board (IRB) of 
the University of New Hampshire.15
Methods
Outcomes considered
Cost-effectiveness is the balance of expenses related to successful 
treatment. Cost-effectiveness analyses are widely accepted 
methods of economic evaluation comparing monetary costs 
with nonmonetary outcomes (eg, increased quality of life, 
improved clinical functioning).16,17 The research methodology 
used for the cost-effectiveness analysis followed the guidelines 
outlined by the Second Panel on Cost-effectiveness in Health 
and Medicine18 and the updated recommendations for this 
Panel’s report.19 Care was taken to follow cost-effectiveness 
guidelines, using standard methodological practices to improve 
comparability and quality, and to include analysis from both a 
healthcare and societal sector perspective. The healthcare sec-
tor included medical costs reimbursed by third-party payers as 
well as paid out-of-pocket by patients.
Treatment completion rate is the full completion of the desig-
nated treatment program. This is one of the strongest predic-
tors of successful therapy.20,21 Clients who complete substance 
abuse treatment are “more likely to remain abstinent, have 
fewer relapses, higher level of employment and higher wages, 
fewer readmissions, less future criminal involvement, and bet-
ter health” (p. 130).22 As further outlined by the National 
Institute on Drug Abuse (NIDA) (2018): “. . .the biggest 
drawback to therapeutic communities is the large percentage of 
enrollees (⩾75%) who never complete treatment” (p. 1).22
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Clinical healthcare outcomes measure the effectiveness of 
behavioral healthcare by focusing on who needs treatment, 
how they access treatment, what treatment works best in those 
settings, and how to keep people engaged in treatment long 
enough to benefit clients.2 For example, clients who remain in 
treatment for longer periods of time are more likely to achieve 
maximum benefits.7 Specifically, treatment episodes for 
⩾3 months is often a predictor of successful outcomes.16
Societal outcomes hold great importance in the treatment of 
substance abuse. For example, substance abuse treatment is 
associated with reductions in crime rates, reduced incarcera-
tion, public safety benefits, positive transition from criminal 
justice system to the community, and is more cost effective 
than prison or other punitive measure.23 The societal sector 
also included expenses related to medical care, infectious 
issues, pre and postnatal care, mental disorders, government 
and private transfer payments, and other programs (eg, 
unemployment benefits, welfare payments, disability 
benefits).23-25
Post-Acute Care Treatment Programs
Outdoor behavioral healthcare. OBH can be defined as a 24-hour 
intermediate outdoor group living environment that includes 
group, individual, and family therapy. These therapies are 
designed to address behavioral and emotional issues by utiliz-
ing treatment modalities centered on nature, challenging expe-
riences combined with reflection/mindfulness, interpersonal 
development, and intrapersonal growth.
Treatment as usual. There are a number of choices for treat-
ment with mental health and substance abuse issues. As identi-
fied in the Treatment Episode Data Set2 the most commonly 
accessible options for treatment service or state jurisdiction for 
substance use or mental health issues were: outpatient (39%), 
detoxification (21%), intensive outpatient (13%), short-term 
residential (10%), long-term residential (8%), hospital residen-
tial (>1%). The percentages associated with each category rep-
resent the percentage of discharges that occurred in the United 
States in 2016.2
No structured treatment. This implies no systematic post-
acute treatment (ie, only acute episodic care is involved), and 
with estimated rates of visits to an emergency room (ER), inpa-
tient stays, and rates of premature death.25
Participants
The cost–benefit analysis was assessed based on treating a sim-
ulated group of 13 to 17-year-old comorbid adolescent sub-
stance users (eg, ICD10, alcohol, F10.20; marijuana, F11.20, or 
opioid, F12.20) also presenting a comorbid clinical diagnosis 
(ICD 10) of at least one of the following: depression (F32.2), 
anxiety (F41.1), or suicidal ideation (Z91.5, Z91.89). After 
admission and evaluation at emergency services, clients were 
discharged to an adolescent hospital-based inpatient psychiat-
ric unit before TAU or OBH (the cost of the precipitating uti-
lization events is not included in the study).
Consequences of the program were based on estimates of 
health care utilization, health status, and quality-adjusted life 
years compared to expected rates in NST, completed treatment, 
and partial treatment. Valeck’s26 research was used to simulate 
the number of individuals admitted to a treatment program and 
the number of individuals requiring treatment in emergency 
rooms and inpatient stays for the NST group.27 These numbers 
were based on 130 people who abused or were dependent [on 
opioids], 32 of this group (24.6%) required “emergency depart-
ment visits for misuse or abuse,” 10 (7.7%) were admitted into 
“inpatient admissions for abuse,” and one who died (0.8%). 
Such simulations are critical in the development of cost–benefit 
and cost-effectiveness in the behavioral healthcare field.28
Using the level of care required to treat the identified cli-
ents, program costs for both OBH and TAU were determined 
through surveys conducted with 18 OBH programs and 11 
TAU programs. NST were assumed to be zero for these 
analyses.
Program benefits were based on three different scenarios:
(1) Short-term utilization benefit: These were determined 
from estimated ER rates for emergency and intensive 
inpatient use for substance abusers with the assumption 
that expected utilization for NST would not be experi-
enced by those completing 100% of the course of post-
acute treatment. The median cost of emergency room29 
and inpatient services was used and adjusted for medical 
inflation.30
(2) Health benefits: Based on the findings from DeMille 
et al,12 2.75 was indexed for OBH, 1.0 for TAU, and 0.0 
for NST. Cost–benefit was indexed to TAU where the 
cost of TAU was expected to bring a benefit of 1.0; and 
the program cost of OBH would be indexed to the same 
value. Thus, if the cost of OBH was the same as TAU, the 
benefit would be equal to 2.75; if the cost of OBH was 
less than TAU, but benefit would be >2.75; conversely if 
the cost of OBH was greater than TAU, the benefit 
would be <2.75.12
(3) Long-term utilization (based on premature death esti-
mates): This was based on estimates of the number of 
deaths in the NST substance abuse population where 
100% completion of either program would result in these 
values being zero.2 This figure was used to estimate the 
years of life lost31 and the economic value of each year of 
life lost32 adjusted for medical inflation.
Cost Factors
The average per diem charge and length of treatment for OBH 
was determined by a random selection of 10 OBH Council 
4 Substance Abuse: Research and Treatment 
(OBHC) members from the membership records in the 
Winter of 2019.33 The median per diem cost for these OBH 
members on November 1, 2018 was $561 per day with the 
average length of treatment being 90 days.34
The average per diem charge and length of treatment for 
TAU was determined from the random selection of 10 TAU 
programs from the National Association for Therapeutic 
Schools and Programs Membership Handbook who were not 
also OBHC members in the Winter of 2019. The median per 
diem charge for TAU on November 1, 2018 was $900 with 
the average length of treatment stay set at 90 days to match 
the same length of time used for OBH (note the minimum 
level or dosage of effective treatment has been identified by 
SAMHSA, 2018 to be 90 days for substance use treatment).2
In order to determine the societal benefits from OBH and 
TAU, two non–health care-related issues were used to assign 
the annual costs associated with SUD ($74.2 billion in 2013 
dollars). Twenty-six percent of this cost was due to a loss of 
worker productivity and 9.7% due to criminal justice.35 The 
total cost burden associated with these two non–health care-
related issues were adjusted to 2018 dollars and calculated on a 
per person cost.
Results
Table 1 presents the combined factors of program costs for one 
person as well as 100, program completion rates. As one can 
see, the program costs for OBH were approximately $17 000 
less for each than TAU programing costs.
Table 2 summarizes the cost burden shouldered by Society 
when a person falls into the category of “no structured treat-
ment.” Some of the expenses needing to be covered by this seg-
ment of our society include ER visits, inpatient delivery of 
services, premature death occurrences, losses in Quality in Life 
Years (QALY) and societal factors (eg, worker productivity, 
criminal justice issues)
Table 3 examines what occurs when all of costs and ben-
efits are combined together, both when program completion 
is simulated for 100% (Table 3A) and when the actual pro-
gram completion rates are applied for OBH and TAU (Table 
3B). In the simulated cohort of 100 individuals, the short 
and QALY benefits were the same. But because the costs 
were lower, the short-term cost–benefit of OBH was 60% 
more, the value of reduced premature death was 60% more 
as were other societal benefits (eg, worker productivity, 
criminal justice issues), and the value of greater treatment 





MUlTiPliER fOR TREATMENT 
COSTS AND BENEfiT
iNSURANCE PAy (80% Of 
AllOWED CHARGES)
TREATMENT COMPlETiON 
RATES USED iN MODElS
NST 0% 0.00 $0.00 0.00%
OBH 100% 1.00 $28 274 94.00%
⩾75% to <100 0.88 $24 726 1.50%
⩾50% to <75% 0.63 $17 671 1.50%
⩾25 to <50% 0.38 $10 603 1.50%
0 to <25% 0.13 $3 534 1.50%
TAU 100% 1.00 $45 360 37.20%
⩾75% to <100 0.88 $39 667 15.70%
⩾50% to <75% 0.63 $28 350 15.70%
⩾25 to <50% 0.38 $17 010 15.70%
Table 2. Benchmark: expectation of NST.
CATEGORy ER viSiT* iP STAy** PREMATURE DEATH QAly (yEARS lOST) SOCiETAl iSSUES (ANNUAl)#
Expected rate per 100 25 8 0.77 41.7 NA
value (insurance paid rate) $959 $6 158 $67 537 NA $948
value per 100 $23 971 $49 262 NA $2 166  377 $94 757
*Median insurance pay.
**Median insurance pay: $1338.64 per day @ 4.6 days.
#Worker productivity + criminal justice issues.
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benefit was 259% better in OBH. The cost of treatment was 
higher in OBH and TAU than the short-term benefit of 
reduced ER and IP, but this is the case with many health 
interventions.
Table 4A shows results adjusted for empirically derived 
completion rates for the outcomes of utilization and QALYs 
(based on expected deaths). Assuming a cohort of 100 indi-
viduals combined with each program’s completion rate (94% 
for OBH, and 37% for TAU), the cost and benefits (ie, utiliza-
tion) were calculated based on multipliers in Table 1. In this 
situation, the price of OBH was 12% less than TAU, the short-
term utilization and QALY benefits were 41% better, short-
term CBA of OBH was 60% better, the value of reduced 
premature death was 6% more.
Table 4B shows results adjusted for empirically derived 
completion rates for the outcomes of utilization and QALYs 
(based on expected deaths). Assuming a cohort of 100 indi-
viduals combined with each program’s completion rate (94% 
for OBH, and 37% for TAU), the cost and benefits (ie, utili-
zation) were calculated based on multipliers in Table 1. In this 
situation, the value of YOQ benefits were 362% better and 
the combined value of issues related to worker productivity 
and criminal justice issues was 60% better in OBH compared 
to TAU.
Discussion
OBH is less expensive than TAU when patients are 100% 
successful in completing treatment; and it is also less expen-
sive if the completion rate is based upon empirical rates 
found in the literature (ie, 94% for OBH, 37% for TAU). A 
90-day treatment for both OBH and TAU was used for cal-
culations—the recommended minimum by SAMSHA for 
SUD treatment. Given its higher rate of completion, this 
study shows OBH is more cost effective post-acute care 
treatment regimen for SUD than TAU with regard to short-
term utilization, health improvement, longevity, and general 
societal benefits of improved worker productivity and crimi-
nal justice issues.
It is important to note this comparison only used 1 year cost 
for utilization and societal benefits; and it is a very defensible 
assumption that these benefits are cumulative, and the actual 
dollars saved will improve year after year.





PROGRAM TyPE PROGRAM COSTS PER 100 HEAlTH CARE UTilizATiON PREMATURE DEATHS
TOTAl PAy PER 
PERSON
TOTAl PAy PER 100 BENEfiTS CBA BENEfiTS CBA
0.0% NST $0.00 $0 $0.00 0.0000 $0.00 0.0000
100.0% OBH (90 days) $28 274.40 $2 827  440 $73 232.83 0.0259 $5 195  150 1.8374
100.0% TAU (90 days) $45 360.00 $4 536  000 $73 232.83 0.0161 $5 195  150 1.1453
 Delta (OBH-TAU) −$17 086 −$1 708  560 $0 0.0098 $0.00 0.6921
 Percent difference 
(to TAU)
−37.67% −37.67% 0.00% 60.43% 0.00% 60.43%




PROGRAM TyPE PROGRAM 
PAy PER 100








COSTS (TO TAU) PER 100
iNDExED yOQ 
iMPACT PER 100
CBA BENEfiTS iN 1 
yEAR
CBA
0% NST 0 0.00 0.00 0.0000 $0.00 0.000
100% OBH (90 days) $2 827  440 76.59 275.00 3.5906 $94 757 0.034
100% TAU (90 days) $4 536  000 100.00 100.00 1.0000 $94 757 0.021
 Delta (OBH-TAU) −$1 708  560 −23.41 175.00 2.5906 $0.00 0.013
 Percent difference 
(to TAU)
−37.67% −23.41% 175.00% 259.06% 0.00% 60.43%
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The findings of this study clearly demonstrate the greater 
outcomes of OBH for post-acute adolescents to both TAU 
and NST, and at a reduced program cost compared to TAU. 
One of the questions clearly becomes which clients should be 
considered for OBH and which clients should be considered 
for TAU. If insurance companies increase their coverage of 
these SUD post-acute care treatment systems, it is essential to 
understand if the criteria for entry into both programs are 
identical. Or does OBH—the more novel program—require 
additional rules of admission. The general requirements for 
standard therapy for post-acute substance abuse therapy have 
been outlined above and guidelines for TAU is well described 
and documented.14
One of the strengths of OBH programing with immediate 
post-acute clients is its ability to address clients at different 
stages of change, most notably the precontemplation state of 
change.34 Precontemplation is a state where clients often deny 
any need to change. At this stage, clients project externalizing 
blaming behaviors, a lack of ownership for the problems, and no 
motivation to change. What OBH does effectively in producing 
client change is guide a client behavior from this stage to a state 
of contemplation.36 At this stage, clients obtain a new awareness 
of their problems, own their responsibility for the problem, and 
consider healthy change to address their therapeutic issue. A 
healthy change process from this adaptation emerges that trans-
forms clients’ perspectives in the primary phase of treatment.37 
For some individuals this may not be enough treatment to assist 
them in completing their transformation to lasting healthy 
change. In such cases the secondary programing for change is 
necessary beyond the first 90 days of treatment. Thus, the entry 
criteria for both OBH and TAU is identical, even for those who 
are resistant to change at the beginning of therapy.
Two extremely important and well-developed mechanisms 
have recently occurred to help insurers as well as clients iden-
tify those OBH programs that possess both the clinical and 
ethical qualities sought to deliver best practices, evidence-based 
research, and effective treatment.
The first mechanism outlines the clinical criteria for OBH 
guidelines for children and adolescents.38 Vetted by the 
Outdoor Behavioral Healthcare Research Council scientists 
(obhrc.org), this document provides clear guidelines which 
define medical necessity, examples of services and programs 
that generally do not meet the clinical criteria of OBH, the 
well-researched factors of safety, effectiveness, quality, and 
costs, program requirements and expectations, and criteria for 
treatment admission as well as continuation and discharge.38
The second mechanism is an accreditation process for OBH 
that delivers 26 years of experience in ongoing development for 
the OBH field. Coordinated by the Association for Experiential 
Education (AEE), the accreditation program maintains a 
strong focus of objectivity and transparency in its 27-step pro-
cess.39 Many facets are covered by the accreditation process, 
Table 4A. CBA healthcare utilization and premature deaths: Comparative effectiveness of OBH, TAU, and NST in adolescents using treatment 




PROGRAM TyPE PROGRAM COSTS PER 100 UTilizATiON QAly (BASED ON 
ExPECTED DEATHS)




BENEfiTS CBA BENEfiTS CBA
0.0% NST $0.00 $0.00 $0.00 NA $0.00 NA
94.0% OBH (90 days) $28,274 $2 657  794 $68 839 0.02590 $4 883  441 1.84
1.5% $24 726 $37 089 $961 0.02590 $68 147 1.84
1.5% $17 671 $26 507 $687 0.02590 $48 705 1.84
1.5% $10 603 $15 904 $412 0.02590 $29 223 1.84
1.5% $3 534 $5 301 $137 0.02590 $9 741 1.84
SUM $27 426 $2 742 596 $71 035 0.02590 $5 039  256 1.84
37.2% TAU (90 days) $45 360 $1 687  392 $27 243 0.01614 $1 932  596 1.15
15.7% $39 667 $622 777 $10 055 0.01614 $713 276 1.15
15.7% $28 350 $445 095 $7 186 0.01614 $509 774 1.15
15.7% $17 010 $267 057 $4 312 0.01614 $305 864 1.15
15.7% $5 670 $89 019 $1 437 0.01614 $101 955 1.15
SUM $31 113 $3 111 340 $50 232 0.01614 $3 563  465 1.15
 Delta (OBH-TAU) −$3 687 −$368 744 $20 803 0.00976 $1 475  791 0.69
 Percent difference (to TAU) −11.85% −11.85% 41.41% 60.43% 41.41% 60.43%
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including philosophical, therapeutic, educational, and ethical 
principles; program government, management operations, 
therapeutic assessment, delivery, oversight and evaluation; 
oversight of adventure experiences; staffing, transportation, 
equipment, nutrition, and hygiene; the technical aspects of 
OBH experiences; supervision of clients, therapist qualifica-
tions, and risk management procedures.39
Limitations
The current study builds upon a growing literature showing the 
effectiveness of OBH treatment. The study draws upon multi-
ple, yet similar, settings within OBH and TAU treatments in 
order to better generalize findings. However, larger samples 
and additional varieties of settings regarding both interven-
tions would strengthen the generalizability of the findings. In 
addition, one large question not in this study that merits close 
scrutiny is the question of dosage for OBH programing (as 
well as TAU), not addressed in the current study. Certainly 
research should seek to discern just how many days are needed 
to achieve the level of significant clinical differences caused by 
OBH programing. Such is also the case for several levels of 
TAU (eg, residential treatment). While the average OBH pro-
graming days in the study was 90 days, the range of OBH 
treatment days was 1-327 days of treatment. This certainly will 
be crucial in the decision by reimbursers and insurance payers 
in their efforts to make the most beneficial, yet economical, 
decisions for clients.
The preceding comparison of the completion rates, relative 
costs, effectiveness, and benefits of OBH and TAU demonstrates 
the potential benefit of insurance coverage of all types of post-
acute SUD treatment, especially OBH. However, further inquiry 
is needed to substantiate and elaborate upon these initial findings. 
Future directions in the movement toward insurance coverage of 
post-acute SUD treatment should further address additional eco-
nomic evaluation of OBH and TAU, implications of insurance 
coverage for OBH and TAU, the significance of the Affordable 
Care Act and growing payment of services by the public sector, 
and thoughts on more direct involvement in SAMHSA’s special-
ized mental health treatment approaches programs.
Note that relapse figures for the three groups involved in the 
study were not included in the calculations. Future studies on 
relapse from OBH programing are certainly important to 
study in the near future.
Conclusion
Professionals can use the information provided in this article on 
research outcomes, cost-effectiveness, and treatment completion 
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(TO TAU) PER 100
iNDExED yOQ 
iMPACT PER 100
CBA BENEfiTS iN 1 
yEAR
CBA
0.0% NST $0 0.00 0.00 NA $0.00 NA
94.0% OBH (90 days) $2 657 794 0.62 258.50 4.41 $89 072 0.034
1.5% $37 089 0.55 3.61 4.41 $1 243 0.034
1.5% $26 507 0.39 2.58 4.41 $888 0.034
1.5% $15 904 0.23 1.55 4.41 $533 0.034
1.5% $5 301 0.08 0.52 4.41 $178 0.034
SUM $2 742  596 0.60 266.75 4.41 $91 914 0.034
37.2% TAU (90 days) $1 687  392 1.00 37.20 1.00 $35 250 0.021
15.7% $622 777 0.87 13.73 1.00 $13 010 0.021
15.7% $445 095 0.62 9.81 1.00 $9 298 0.021
15.7% $267,057 0.38 5.89 1.00 $5 579 0.021
15.7% $89 019 0.13 1.96 1.00 $1 860 0.021
SUM $3 111  340 0.69 57.79 0.84 $64 996 0.021
 Delta (OBH-TAU) −$368 744 −0.081 208.96 3.57 $26 918 0.013
 Percent difference 
(to TAU)
−11.85% −11.85% 361.56% 423.62% 41.41% 60.43%
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rates for decision making. As the new era of behavioral health 
parity begins, effectiveness studies such as this one should help 
stakeholders improve decision making processes. For example, 
insurance providers could use these three factors to determine 
the most effective treatment at the lowest cost. Healthcare advo-
cates and families would apply their findings to increase these 
successes in attaining proper insurance reimbursement for a 
family’s expenditures. State insurance commissioners could use 
these factors to advocate for appropriate coverage for consumers 
in need of post-acute SUD care in their state. Behavioral health-
care programing that targets post-acute SUD care would apply 
these factors to increase their client base.
Author Contribution
MG led the concept development of the project, manuscript 
writing, and revision process. TW and MG were responsible 
for the interpretation and synthesis of cost-benefit analyses 
data, with input from BT. MG and BT were responsible for 
collecting OBH data and analyses, study design, and collec-
tion/statistical analysis and site data. MG, TW, and BT pro-
vided the majority of the manuscript development. AT 
provided an important objective critique and feedback of the 
content and process. MU assisted with the cost-benefit analysis 
processes and NB assisted with the rewriting process. All 
authors read and approved the final manuscript.
ORCID iD
Michael Gass  https://orcid.org/0000-0003-2050-3951
RefeRenCes
 1. Peterson-Kaiser Health System Tracker. Exploring Mental and Behavioral and 
Substance Abuse. Washington, DC: NIDA; 2018.
 2. Substance Abuse and Mental Health Services Administration, Center for Behavioral 
Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2016. Admissions 
to and Discharges from Publicly Funded Substance Use Treatment. Rockville, MD: Sub-
stance Abuse and Mental Health Services Administration; 2018:625.
 3. Hedegard H, Curtin SC, Warner M. Suicide rates in United States continue to 
increase. NCHS Data Brief. 2018;330: 1–8.
 4. National Survey on Drug Use and Health. Substance Abuse and Mental Illness Pre-
vention. Washington, DC: NSDUH; 2018.
 5. Substance Abuse and Mental Health Services Administration, Office of the Sur-
geon General. Facing Addiction in America: The Surgeon General ’s Report on Alco-
hol, Drugs, and Health. Washington, DC: U.S. Department of Health and 
Human Services; 2016.
 6. National Institute of Mental Health. Children and Mental Health. Washington, 
DC: NIDA; 2018.
 7. Gold AK, Otto MW, Deckersbach T, Sylvia LG, Nierenberg AA, Kinrys G. 
Substance use comorbidity in bipolar disorder: a qualitative review of treatment 
strategies and outcomes. Am J Addict. 2018;27:188–201.
 8. Peterson-Kaiser Health System Tracker. What Are the Current Costs and Outcomes Related 
to Mental Health and Substance Use Disorders? Washington, DC: NIDA; 2018.
 9. Gass MA (ed.). Manual of Accreditation Standards for Outdoor Behavioral Health-
care Programs. Boulder, CO: AEE; 2014.
 10. Bowen D, Neill J, Crisp S. Wilderness adventure therapy effects on the mental 
health of youth participants. Eval Program Plann. 2016;58:49–59.
 11. Bettmann JE, Gillis HL, Speelman EA, Parry KJ, Case J. A meta-analysis of 
wilderness therapy outcomes for private pay clients. J Child Fam Stud. 
2016;25:2659–2673.
 12. DeMille S, Tucker AR, Gass MA, et al. The effectiveness of outdoor behavioral 
healthcare with struggling adolescents: a comparison group study contribution 
for the special issue: Social Innovation in Child and Youth Services. Child Youth 
Serv Rev. 2018;88:241–248.
 13. OQ Measures. Youth Outcome Questionnaire (YOQ ). http://www.oqmea-
sures.com. Accessed June 20, 2019.
 14. Lewis SF. A novel investigation of substance use outcomes in substance-specific 
outdoor behavioral healthcare programs. JTSP. 2018;10:102–121.
 15. IRB #3984. Review Level: Full, Approval Expiration Date: 02-May-2020.
 16. Gordon JA. Director’s Messages. National Institute of Mental Health Director’s 
Office. Washington, DC: NIMH; 2016:6.
 17. National Information Center on Health Services Research and Health Care 
Technology (NICHSR). Cost analysis methods. 2019. http://www.nlm.nih.gov/
nichsr/hta101/ta10106.html
 18. Saunders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, meth-
odological practices, and reporting of cost-effectiveness analyses: second panel on 
cost-effectiveness in health and medicine. JAMA. 2016;316:1093–1103.
 19. Wisemen V, Jan S. Updated recommendations for cost-effectiveness studies. 
JAMA. 2017;317:89–90.
 20. Harley M, Pit SW, Rees T, Thomas S. Completion rates and psychosocial inter-
vention effectiveness in an Australian substance use therapeutic community. 
Subst Abuse Treat Prev Policy. 2018;13:1–11.
 21. Stahler GJ, Mennis J, Ducette JP. Residential and outpatient treatment comple-
tion for substance use disorders in the U.S.: moderation analysis by demographics 
and drug of choice. Addict Behav. 2016;58:129–135.
 22. U.S. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A 
Research-Based Guide. 3rd ed. Vol. 3. Washington, DC: NIDA; 2018:67.
 23. Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid 
overdose, abuse, and dependence in the United States. Med Care. 
2016;54:901–906.
 24. Stewart MT, Horgan CM. Health services and financing of treatment. Alcohol 
Res Health. 2011;33:289–394.
 25. Ettner SL, Huang D, Evans E, et al. Benefit-cost in the California treatment 
outcome project: does substance abuse treatment “pay for itself ”? Health Serv Res. 
2006;41:192–213.
 26. Valuck R. The Opioid Crisis in Colorado: Unfinished Business. Denver: Colorado 
Health Symposium; 2018.
 27. Agency for Healthcare Research and Quality. Table 6: Emergency Room Ser-
vices-Median and Mean Expenses per Person with Expense and Distribution of 






 28. Maloney S, Haines T. Issues of cost-benefit and cost-effectiveness for simulation 
in health professions education. Advances in Simulation. 2016;1:13.
 29. Moore B, Levit K, Elixhauser A. Costs for Hospital Stays in the United States, 
2012. HCUP Statistical Brief #181. 2014. https://www.hcup-us.ahrq.gov/
reports/statbriefs/sb181-Hospital-Costs-United-States-2012.pdf
 30. Bureau of Labor Statistics. Series Title: Medical care in U.S. city average, all 
urban consumers, not seasonally adjusted. https://data.bls.gov/cgi-bin/
surveymost
 31. Project Know: Understanding Addiction. Cutting it Short. 2017. https://www.
projectknow.com/discover/cutting-it-short/
 32. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the 
value of modern medicine say about the $50,000 per quality-adjusted life-year 
decision rule? Med Care. 2008;46:349–356. https://insights.ovid.com/
pubmed?pmid=18362813. There is some disagreement regarding this as can be 
seen in: Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — 
the curious resilience of the $50,000-per-QALY threshold. Perspective. N Engl 
J Med. 2014. http://www3.med.unipmn.it/papers/2014/NEJM/2014-08-28_
nejm/nejmp1405158.pdf
 33. Gass MA. 2019 OBH Marketing Report. Durham, NH: Outdoor Behavioral 
Healthcare Research Center; 2019:1–20.
 34. DiClemente CC. Addiction and Change: How Addictions Develop and Addicted 
People Recover. 2nd ed. New York, NY: Guilford Press; 2018.
 35. French MT, Zavala SK, McCollister KE, Waldron HB, Turner CW, 
Ozechowski TJ. Cost-effectiveness analysis of four interventions for adolescents 
with a substance use disorder. J Subst Abuse Treat. 2008;34:272–281.
 36. Prochaska J, Prochaska J. Changing to Thrive: Using the Stages of Change to Over-
come the Top Threats to Your Health and Happiness. Center City, MN: Hazelden 
Publishing; 2016.
 37. Connors GJ, DiClemente CC, Velasquez MM, Donovan DM. Substance Abuse 
Treatment and the Stages of Change: Selecting and Planning Interventions. 
New York, NY: Guilford Press; 2016.
 38. Gass MA, Berhens E, Bettman J, et al. Clinical criteria for Outdoor Behavioral 
Healthcare Programs. Durham, NH: Outdoor Behavioral Healthcare Research 
Center, University of New Hampshire; 2019.
 39. Gass MA (ed.). Accreditation Standards for Outdoor Behavioral Healthcare Pro-
grams. Boulder, CO: AEE; 2014.
